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Sir,
We have read with great attention the letter sent by Nagelkerke
et al. This team has in the past published one of the most
interesting articles on housekeeping gene (HKG) variations
(de Kok et al, 2005). On the basis of their own previous laboratory
experience and specific data obtained on hypoxia experiments
(Mujcic et al, 2009), they reported that whether 18S rRNA was not
stable enough to be used to normalise results in human tissues, it
seemed to be a good HKG in cell lines to compensate input, reverse
transcription, and PCR efficiency. As 18S rRNA was not one of our
selected HKGs in our study, they rightly suggested studying
its expression on our hypoxic cDNA bank. For this purpose, we
used the same 18S primers they used in their trials (18S_W:
F-agtccctgccctttgtacaca and R-gatccgagggcctcactaaac) and per-
formed quantitative real-time PCR (qRT-PCR), as described earlier
(Caradec et al, 2010), on four prostate (PNT2 and LNCaP), kidney
(HEK) and breast (MCF-7) cell lines treated with four oxygen
concentrations (1, 5, 10, and 20%).
Results first show that 18S amplification is constantly detected at
around 15 PCR cycles threshold (Ct). As to cell variability, r18S
expression seems to be relatively stable (coefficient of variation
(CtCV%) o3%) in three cell lines, except in LNCaP prostate
tumor cell line where CtCV% is above 6%. These results have
been confirmed using a newly designed set of 18S specific
primers (18S_C: F-catggccgttcttagttggt and R-cgctgagccagtcagt
gtag) (Figure 1). When 18S results were compared with those we
already obtained with other HKG (Caradec et al, 2010), we found
that 18S appears to be the best one in HEK cell line and the second
best one in PNT2 cell lines (Table 1). However, it is likely to be
one of the worst in LNCaP and MCF-7.
Our study results do neither corroborate nor contradict the
conclusions raised by Nagelkerke et al. They reported r18S as
the best HKG to normalise results in hypoxia experiments, and we
found that it may be a good one in two out of the four cell lines we
studied in hypoxia conditions. Whereas r18S could be a good and
reasonable choice for some cell lines, it would not be the right one
for others. As stated by Nagelkerke et al, this holds also true for
in vivo systems as the compensation system that is convenient for
a dedicated in vitro model is not the one necessarily recommended
when tissues have to be studied. That is why we persist in arguing
that every HKG must be tested before experiments to choose the
best one: this necessary step will determine result’s reliability, and
should be performed for every new study design. As we tested
r18S, an important issue has to be discussed here regarding its use
as a dedicated compensate for input, RT and PCR efficiency.
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Figure 1 r18S variations in PNT2, MCF-7, LNCaP, and HEK cell lines
grown in different hypoxic conditions (1, 5, 10, and 20% oxygen). Box plots
represent cycle threshold (Ct) variations measured with different primers
(black box: 18S_W, white box: 18S_C, value representing CtCV% is
indicated below corresponding box plot). r18S expression was quantified
by qRT-PCR in duplicates in three independent experiments.
Table 1 Housekeeping genes ranking according to their stability in each
cell line
PNT2 LNCaP MCF-7 HEK
18S_C 6 12 10 1
18S_W 2 11 12 2
ACTB 9 4 5 12
ATP5G3 1 5 3 10
B2M 12 3 9 7
GAPDH 8 2 11 4
GUSB 11 8 4 3
HRPT1 4 7 8 8
PGK1 7 9 9 5
PPIA 10 10 7 9
TBP 5 1 1 11
TFRC 3 6 2 6
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a largely lower level than r18s (generally over 25 up to 35–36 Ct –
over this limit, results are likely to be uninterpretable). As a
difference of 10–15 Ct corresponds to a difference of 10
3-t o
10
5-folds in expression level, it remains to establish whether a
highly expressed gene could serve to normalise weakly expressed
transcripts. There are no clear evidences that transcripts present
at large number of copies are extracted at the same yield level
as scarser ones. Moreover, it could also be the same for cDNA
production as it is tempting to speculate that reverse transcriptase
may be more efficient when large amount of substrate is present
than for tiny represented targets that have a stochastic probability
to be similarly processed.
As RNA extraction protocols, as well as RT or PCR efficiencies
remained strongly laboratory reagents, protocols, and instrument
dependents, worldwide standardisation of these techniques is still
strongly mandatory. As these standards are not available yet, using
HKG remains an interesting option that presupposes that HKGs
have been carefully tested and controlled in the experimental
system they have to be used.
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